Rivoceranib Sustained Release Microspheres for the Treatment of Angiogenesis
발표자
()
초록
내용
Rivoceranib is an oral small molecule tyrosine kinase inhibitor selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), one of the most powerful receptors regulating neovascular signaling. However, rivoceranib is insoluble and clears rapidly due to its small molecular weight. Therefore, a formulation step is required to improve the instability properties and microsphere formulations are suitable to address these issues. Emulsion has dispersion system and dispersion medium liquid state, in which one solution is dispersed into another continuous phase. The o/w single emulsion and solvent evaporation methods are most widely used to prepare microspheres encapsulating hydrophobic drug compounds. We prepared rivoceranib-containing microspheres using o/w single emulsion and evaporation methods for efficient drug delivery. The experimental results show that rivoceranib microspheres are expected to be used in the prevention and treatment of ocular diseases related to corneal neovascularization.